Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Roflumilast (500mcg) Tablet
Therapeutic Category
Pulmonary, Respiratory
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Rofumist Tablet (Roflumilast 500 mcg) is a selective PDE-4 inhibitor used to reduce inflammation and prevent exacerbations in chronic obstructive pulmonary disease (COPD) and chronic bronchitis. It works by decreasing lung inflammation and improving airflow, making it a vital maintenance therapy for respiratory patients.
Rofumist Tablet is widely prescribed by pulmonologists and respiratory specialists, ensuring consistent market demand. It offers a promising PCD pharma franchise and manufacturing opportunity for companies looking to expand their respiratory segment portfolio. Backed by high prescription value and clinical reliability, Rofumist is ideal for B2B distribution, export, and competitive franchise pricing across India.
Common side effects may include headache, nausea, diarrhea, weight loss, or insomnia. Rarely, patients may experience mood changes, anxiety, or allergic reactions. Any severe or persistent side effects should be reported to a healthcare professional promptly.
Rofumist Tablet is indicated for the maintenance treatment of severe COPD associated with chronic bronchitis and a history of frequent exacerbations. It helps in preventing flare-ups, improving airflow, and reducing symptoms like shortness of breath, coughing, and chest tightness.
Take Rofumist Tablet exactly as prescribed by your doctor, usually once daily with or without food. It is not a rescue medication and should not be used to treat sudden breathing problems. Use with caution in patients with liver impairment, depression, or significant weight loss. Regular monitoring of body weight and mental health is advised during prolonged therapy.
Store Rofumist Tablet in a cool, dry place below 25°C, protected from direct sunlight and moisture. Keep out of reach of children and use only within the expiry period mentioned on the packaging.
Composition : Rifaximin (200mg)
Composition : Rifaximin (400mg)
Composition : Rifaximin (550mg)
Composition : Amoxycillin (875mg) + Clavulanic Acid (125mg)
Composition : Fluconazole (150mg) + Azithromycin (1gm) + Secnidazole (1gm) Tablet
Composition : Amoxycillin (500mg) + Clavulanic Acid (125mg) + Lactobacillus
Composition : Amoxycillin (500mg) + Clavulanic Acid (125mg)
Composition : Amoxycillin (250mg) + Clavulanic Acid (125mg)
Composition : Ambroxol (75mg) + Levocetirizine (5mg) + Montelukast (10mg)
Composition : Azithromycin (250mg) Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Roflumilast 500mcg Tablet has growing demand in the respiratory care, pulmonology, and specialty medicine segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on respiratory and chronic disease management portfolios.
Medical distributors and agencies can benefit from demand for chronic respiratory disease management under specialist supervision. Roflumilast 500mcg is a phosphodiesterase-4 (PDE4) inhibitor used in respiratory care Commonly prescribed to help reduce the risk of exacerbations in patients with severe Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis as advised by healthcare professionals Helps reduce airway inflammation and supports long-term respiratory disease management Used as part of a comprehensive COPD treatment plan and is not intended for the relief of acute bronchospasm Frequently utilized in pulmonology clinics, hospitals, and specialty respiratory care centers Requires regular medical monitoring and adherence to prescribed therapy Widely prescribed by pulmonologists and respiratory medicine specialists This strengthens a comprehensive respiratory and chronic care portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Roflumilast 500mcg Tablet with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and medical agencies benefit from specialty respiratory care market opportunities, consistent prescription demand, repeat purchases, reliable supply chain support, and attractive margins in the pulmonology segment.
Interested distributors, stockists, and wholesalers can partner with Cafoli LifeCare Pvt Ltd to access lucrative PCD pharma franchise opportunities across India. With exclusive monopoly rights, extensive promotional support, high-quality pharmaceutical products, attractive business margins, and dependable logistics support, Cafoli LifeCare Pvt Ltd helps franchise partners build a successful and profitable pharmaceutical business.